Adenosine-anchored triphosphate subsite probing: Distinguishing between HER-2 and HER-4 tyrosine protein kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 20, 2003, Pages 3587-3592

  Liu, Fei ^a   Johnson, Eric F ^b   Austin, David J ^a   Anderson, Karen S ^b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HETEROCYCLIC COMPOUND; PHOSPHATE; PROTEIN TYROSINE KINASE; TRIPHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; ONCOGENE NEU; PROTEIN FAMILY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

EID: 0141516623     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00761-3     Document Type: Article

References (48)

1. (a) Sallese M., Iacovelli L., De Blasi A. Curr. Top. Pharmacol. 3:1997;193
2. (b) Siraganian R.P., Zhang J., Kimura T. Signal Transduct. Mast Cells Basophils. 1999;115.
3. (a) King G.L. Endocr. Updates. 1:1998;181
4. (b) Shankland S.J., Wolf G. Am. J. Physiol. 278:2000;F515.
5. (a) van der Geer P., Hunter T., Lindberg R.A. Annu. Rev. Cell Biol. 10:1994;251
6. (b) Carraway K.L. III, Cantley L.C. Cell (Cambridge, Mass.). 78:1994;5
7. (c) Aaronson S.A. Science. 254:1991;1146.
8. (a) Perez E.A. Cancer Invest. 19:2001;155
9. (b) Gibbs J.B. Science (Washington, D. C.). 287:2000;1969.
10. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y. EMBO J. 15:1996;254.
11. (a) Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. EMBO J. 16:1997;1647
12. (b) Nagy P., Jenei A., Damjanovich S., Jovin T.M., Szollosi J. Pathol. Oncol. Res. 5:1999;255.
13. (a) Junttila T.T., Sundvall M., Maatta J.A., Elenius K. Trends Cardiovasc. Med. 10:2001;304
14. (b) Robinson D., He F., Pretlow T., Kung H.-J. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5958.
15. (a) Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., Lemke G. Nature (London). 378:1995;390
16. (b) Alroy I., Yarden Y. FEBS Lett. 410:1997;83
17. (c) Riese D.J. 2nd, Stern D.F. Bioessays. 20:1998;41
18. (d) Woodburn J.R. Pharmacol. Ther. 82:1999;241.
19. (a) Shih C., Padhy L.C., Murray M., Weinberg R.A. Nature (London). 290:1981;261
20. (b) Plowman G.D., Culouscou J.M., Whitney G.S., Green J.M., Carlton G.W., Foy L., Neubauer M.G., Shoyab M. Proc. Natl. Acad. Sci. U.S.A. 90:1993;1746
21. (c) Cox S., Radzio-Andzelm E., Taylor S.S. Curr. Opin. Struct. Biol. 4:1994;893.
22. The X-ray structure of EGFR kinase domain has recently become available Stamos J., Silwkowski M.X., Eigenbrot C. J. Biol. Chem. 48:2002;46265.
23. (a) Hamby J.M., Showalter H.D.H. Pharmacol. Ther. 82:1999;169
24. (b) Bishop A.C., Kung C.-y., Shah K., Witucki L., Shokat K.M., Liu Y. J. Am. Chem. Soc. 121:1999;627
25. (c) Mendel D.B., Laird A.D., Smolich B.D., Blake R.A., Liang C., Hannah A.L., Shaheen R.M., Ellis L.M., Weitman S., Shawver L.K., Cherrington J.M. Anti-Cancer Drug Des. 15:2000;29
26. (d) Lawrence D.S., Jinkui N. Pharmacol. Ther. 77:1998;81.
27. (a) Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. Science (Washington, D. C.). 265:1994;1093
28. (b) Boschelli D.H. Drugs Future. 24:1999;515
29. (c) Gray N.S., Wodicka L., Thunnissen A.W.H., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., Leclerc S., Meijer L., Kim S.H., Lockhart D.J., Schultz P.G. Science. 281:1998;533.
30. Johnson L.N., Lowe E.D., Noble M.E.M., Owen D.J. FEBS Lett. 430:1998;1.
31. (a) Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Curwen J.O., Hennequin L.F., Thomas A.P., Stokes E.S.E., Curry B., Richmond G.H.P., Wadsworth P.F. Cancer Res. 60:2000;970
32. (b) Sedlacek H.H. Drugs. 59:2000;435.
33. Sequence analyses were performed using the Blast program ( http://www.ncbi.nlm.nih.gov ). The accession codes for proteins analysed are: P04626(HER-2); Q15303(HER-4); 1ATP_E(PKA); and 1BYG_A (Src).
34. (a) Taylor S.S., Radzio-Andzelm E. Curr. Opin. Chem. Biol. 1:1997;219
35. (b) Traxler P., Furet P. Pharmacol. Ther. 82:1999;195.
36. Narayana N., Diller T.C., Koide K., Bunnage M.E., Nicolaou K.C., Brunton L.L., Xuong N.-H., Eyck L.F.T., Taylor S.S. Biochemistry. 38:1999;2367.
37. (a) Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Science. 289:2000;1938
38. (b) Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Cancer Res. 62:2002;4236.
39. (a) Savinov S.N., Austin D.J. Chem. Commun. 18:1999;1813
40. (b) Savinov S.N., Austin D.J. Org. Lett. 4:2002;1415
41. (c) Savinov S.N., Austin D.J. Org. Lett. 4:2002;1419.
42. (a) Liu F., Austin D.J. Tet. Lett. 42:2001;3153
43. (b) Liu F., Austin D.J. J. Org. Chem. 66:2001;8643.
44. Liu F., Austin D.J. Org. Lett. 3:2001;2273.
45. 20 -42.9° (c 0.20, MeOH).
46. m is 5 μM, F is the ratio between the initial rates of phosphorylated peptide formation without or with the presence of the inhibitor, and [S] is the ATP concentration. See: Jan A.Y., Johnson E.F., Diamonti J.A., Carraway K.L. III, Anderson K.S. Biochemistry. 39:2000;9786.
47. HER-2 and phosphorylated HER-2 have different kinase activities. Autophosphorylation of HER-2 results in heterogeneity in enzyme population during the course of assay. The prephosphorylation of HER-2 was performed in excess of ATP for 30 min on ice and quenched with 0.5 M EDTA. The phosphorylated HER-2 was purified by using Bio-Spin™ columns.
48. The complex kinetic characteristics may arise from the small population of HER-2 still remaining from the prephosphorylation reaction of HER-2. See ref 18a.